That's great thanks Ken. This should not come as any surprise to anyone though. The ROW upfront over inflates the previous years earnings and it would have taken sales north of $500 million in 2024 to trigger a similar payment and it should in no way be seen as a failure to not get there that quickly. Sale of the PRV would obviously help but for Neuren to really soar it's all about 2591. If we hit on three or four of the Phase 2s the interest will likely be enormous and Daybue, with only 10-15% ownership still with Neuren, is not so important.
This next couple of months could be a grind. The focus will really be on Acadia to show their claim of short term seasonality is genuine and to hit the mid to upper range of the latest Q1 forecast and predicting decent growth for Q2. This will come out just as the hype around the next Phase 2 for Pitt Hopkins result starts to build so will be interesting where that puts the SP. At this point everyone should be firm on their best and worst case scenarios but until then I can't imagine what could help resurrect things except perhaps the PRV sale ??
- Forums
- ASX - By Stock
- NEU
- Share Price
Share Price, page-9543
-
-
- There are more pages in this discussion • 2,739 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.14 |
Change
-0.040(0.30%) |
Mkt cap ! $1.679B |
Open | High | Low | Value | Volume |
$13.20 | $13.41 | $13.12 | $4.890M | 370.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 997 | $13.14 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.19 | 2000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 997 | 13.140 |
1 | 1291 | 13.130 |
1 | 360 | 13.120 |
5 | 2645 | 13.110 |
10 | 9020 | 13.100 |
Price($) | Vol. | No. |
---|---|---|
13.200 | 2552 | 3 |
13.210 | 1593 | 2 |
13.220 | 2198 | 1 |
13.240 | 2198 | 1 |
13.260 | 2198 | 1 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
LU7
The Breakdown: Lithium Universe talks refinery design and lithium processing in strong preliminary feasibility study for Bécancour
RCE
Phase II clinical trial recruitment for R327G topical gel passes halfway, showing promising results against bacterial skin infections
NEU (ASX) Chart |
The Watchlist
EL8
ELEVATE URANIUM LTD
Murray Hill, MD & CEO
Murray Hill
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online